Physician profile
Michael A Rosenberg
NPI 1073605069
$1,877.17
in general payments reported to CMS, 2019-2025
13 companies · $14.96 in 2025
The $14.96 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $1,543 · 2021: $79.30 · 2022: $56.97 · 2024: $37.64 · 2025: $14.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,543.02 | 2019-2025 | |
| Sanofi Pasteur INC. | $79.54 | 2019-2024 | |
| Glaxosmithkline, LLC. | $59.26 | 2019-2020 | |
| Sobi, INC | $37.23 | 2019 | |
| Cranial Technologies, INC | $32.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.86 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $16.81 | 2021 | |
| Neos Therapeutics, LP | $15.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.70 | 2019 | |
| Aytu Biopharma, INC. | $14.20 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.98 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.17 | 2019 | |
| Merck Sharp & Dohme LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.